Corporate Sustainability Report

Overview

The report presents JB Pharma's FY2023-24 sustainability performance across environmental, social and governance priorities. It highlights a first double materiality assessment, a 13.9% absolute reduction in Scope 1 and Scope 2 emissions, and renewable energy providing 12.1% of total energy demand. The report also sets ESG goals including carbon neutrality in direct operations by FY2032-33. It reports zero cases of injuries, ill-health, fatalities and high-consequence injuries in FY24.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview